Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.

In October 2007, the Company closed a Series A round of financing. This capital will allow the Company to complete a series of studies, over a three year period, that would significantly, de-risk the molecule in preparation for a Phase 3 clinical program.

Corporate Overview | Executive Management | Board of Directors | Clinical Advisory Board